A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects - PubMed (original) (raw)
Clinical Trial
. 2019 Nov;8(8):1009-1031.
doi: 10.1002/cpdd.665. Epub 2019 Feb 21.
Affiliations
- PMID: 30791225
- PMCID: PMC6899822
- DOI: 10.1002/cpdd.665
Clinical Trial
A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects
Gilmour Morrison et al. Clin Pharmacol Drug Dev. 2019 Nov.
Abstract
GW Pharmaceuticals' formulation of highly purified cannabidiol oral solution is approved in the United States for seizures associated with Lennox-Gastaut and Dravet syndromes in patients aged ≥2 years, for which clobazam, stiripentol, and valproate are commonly used antiepileptic drugs. This open-label, fixed-sequence, drug-drug interaction, healthy volunteer trial investigated the impact of cannabidiol on steady-state pharmacokinetics of clobazam (and N-desmethylclobazam), stiripentol, and valproate; the reciprocal effect of clobazam, stiripentol, and valproate on cannabidiol and its major metabolites (7-hydroxy-cannabidiol [7-OH-CBD] and 7-carboxy-cannabidiol [7-COOH-CBD]); and cannabidiol safety and tolerability when coadministered with each antiepileptic drug. Concomitant cannabidiol had little effect on clobazam exposure (maximum concentration [Cmax ] and area under the concentration-time curve [AUC], 1.2-fold), N-desmethylclobazam exposure increased (Cmax and AUC, 3.4-fold), stiripentol exposure increased slightly (Cmax , 1.3-fold; AUC, 1.6-fold), while no clinically relevant effect on valproate exposure was observed. Concomitant clobazam with cannabidiol increased 7-OH-CBD exposure (Cmax , 1.7-fold; AUC, 1.5-fold), without notable 7-COOH-CBD or cannabidiol increases. Stiripentol decreased 7-OH-CBD exposure by 29% and 7-COOH-CBD exposure by 13%. There was no effect of valproate on cannabidiol or its metabolites. Cannabidiol was moderately well tolerated, with similar incidences of adverse events reported when coadministered with clobazam, stiripentol, or valproate. There were no deaths, serious adverse events, pregnancies, or other clinically significant safety findings.
Keywords: cannabidiol; clobazam; drug-drug interaction; pharmacokinetics; stiripentol; valproate.
© 2019 The Authors. Clinical Pharmacology in Drug Development Published by Wiley Periodicals, Inc. on behalf of The American College of Clinical Pharmacology.
Conflict of interest statement
G.B. has consulted for, conducted studies funded by, or received honoraria from GW Research Ltd; K.S. is a consultant of Greenwich Biosciences, Inc; and J.C. and G.M. are employees of GW Research Ltd. Greenwich Biosciences, Inc is the US affiliate of GW Research Ltd.
Figures
Figure 1
Disposition of subjects. Period 1, victim drug alone; period 2, victim and perpetrator drugs in combination.
Figure 2
Treatment schema for DDI clobazam, DDI stiripentol, and DDI valproate. Period 1, victim drug alone; period 2, victim and perpetrator drugs in combination. DDI, drug‐drug interaction.
Figure 3
(A) DDI clobazam. The effect of concomitant administration of 750 mg of cannabidiol bid on plasma concentrations of (i) clobazam and (ii) N‐desmethylclobazam (arithmetic mean ± SD [lower tail is not shown if greater than mean value]). (B) The effect of concomitant administration of 5 mg of clobazam bid on plasma concentrations of (i) cannabidiol, (ii) 7‐OH‐CBD, and (iii) 7‐COOH‐CBD (arithmetic mean ± SD [lower tail is not shown if greater than mean value]). (C) DDI stiripentol. The effect of concomitant administration of 750 mg of cannabidiol bid on plasma concentrations of (i) stiripentol (arithmetic mean ± SD [lower tail is not shown if greater than mean value]). (D) The effect of concomitant administration of 750 mg of stiripentol bid on plasma concentrations of (i) cannabidiol, (ii) 7‐OH‐CBD, and (iii) 7‐COOH‐CBD (arithmetic mean ± SD [lower tail is not shown if greater than mean value]). (E) DDI valproate. The effect of concomitant administration of 750 mg of cannabidiol bid on plasma concentrations of (i) valproate (arithmetic mean ± SD [lower tail is not shown if greater than mean value]). (F) The effect of concomitant administration of 750 mg of valproate, on plasma concentrations of (i) cannabidiol, (ii) 7‐OH‐CBD, and (iii) 7‐COOH‐CBD (arithmetic mean ± SD [lower tail is not shown if greater than mean value]). 7‐OH‐CBD, 7‐hydroxy‐cannabidiol; 7‐COOH‐CBD, 7‐carboxy‐cannabidiol; CI, confidence interval; DDI, drug‐drug interaction; SD, standard deviation.
Figure 3
(A) DDI clobazam. The effect of concomitant administration of 750 mg of cannabidiol bid on plasma concentrations of (i) clobazam and (ii) N‐desmethylclobazam (arithmetic mean ± SD [lower tail is not shown if greater than mean value]). (B) The effect of concomitant administration of 5 mg of clobazam bid on plasma concentrations of (i) cannabidiol, (ii) 7‐OH‐CBD, and (iii) 7‐COOH‐CBD (arithmetic mean ± SD [lower tail is not shown if greater than mean value]). (C) DDI stiripentol. The effect of concomitant administration of 750 mg of cannabidiol bid on plasma concentrations of (i) stiripentol (arithmetic mean ± SD [lower tail is not shown if greater than mean value]). (D) The effect of concomitant administration of 750 mg of stiripentol bid on plasma concentrations of (i) cannabidiol, (ii) 7‐OH‐CBD, and (iii) 7‐COOH‐CBD (arithmetic mean ± SD [lower tail is not shown if greater than mean value]). (E) DDI valproate. The effect of concomitant administration of 750 mg of cannabidiol bid on plasma concentrations of (i) valproate (arithmetic mean ± SD [lower tail is not shown if greater than mean value]). (F) The effect of concomitant administration of 750 mg of valproate, on plasma concentrations of (i) cannabidiol, (ii) 7‐OH‐CBD, and (iii) 7‐COOH‐CBD (arithmetic mean ± SD [lower tail is not shown if greater than mean value]). 7‐OH‐CBD, 7‐hydroxy‐cannabidiol; 7‐COOH‐CBD, 7‐carboxy‐cannabidiol; CI, confidence interval; DDI, drug‐drug interaction; SD, standard deviation.
Figure 3
(A) DDI clobazam. The effect of concomitant administration of 750 mg of cannabidiol bid on plasma concentrations of (i) clobazam and (ii) N‐desmethylclobazam (arithmetic mean ± SD [lower tail is not shown if greater than mean value]). (B) The effect of concomitant administration of 5 mg of clobazam bid on plasma concentrations of (i) cannabidiol, (ii) 7‐OH‐CBD, and (iii) 7‐COOH‐CBD (arithmetic mean ± SD [lower tail is not shown if greater than mean value]). (C) DDI stiripentol. The effect of concomitant administration of 750 mg of cannabidiol bid on plasma concentrations of (i) stiripentol (arithmetic mean ± SD [lower tail is not shown if greater than mean value]). (D) The effect of concomitant administration of 750 mg of stiripentol bid on plasma concentrations of (i) cannabidiol, (ii) 7‐OH‐CBD, and (iii) 7‐COOH‐CBD (arithmetic mean ± SD [lower tail is not shown if greater than mean value]). (E) DDI valproate. The effect of concomitant administration of 750 mg of cannabidiol bid on plasma concentrations of (i) valproate (arithmetic mean ± SD [lower tail is not shown if greater than mean value]). (F) The effect of concomitant administration of 750 mg of valproate, on plasma concentrations of (i) cannabidiol, (ii) 7‐OH‐CBD, and (iii) 7‐COOH‐CBD (arithmetic mean ± SD [lower tail is not shown if greater than mean value]). 7‐OH‐CBD, 7‐hydroxy‐cannabidiol; 7‐COOH‐CBD, 7‐carboxy‐cannabidiol; CI, confidence interval; DDI, drug‐drug interaction; SD, standard deviation.
Figure 4
(A) DDI clobazam. (i) The effect of concomitant administration of 750 mg of cannabidiol bid on individual and geometric mean steady‐state exposure (top panel: Cmax; middle panel: AUCtau; bottom panel: treatment ratios with 90% confidence intervals [CIs]) to clobazam and N‐CLB. (ii) The effect of concomitant administration of 5 mg of clobazam bid, on individual and geometric mean steady‐state exposure (top panel: Cmax; middle panel: AUCtau; bottom panel: treatment ratios with 90%CI) to cannabidiol, 7‐OH‐CBD, and 7‐COOH‐CBD. (B) DDI stiripentol. (i) The effect of concomitant administration of 750 mg of cannabidiol bid on individual and geometric mean steady‐state exposure (top panel: Cmax; middle panel: AUCtau; bottom panel: treatment ratios with 90%CI) to stiripentol. (ii) The effect of concomitant administration of 750 mg of stiripentol bid, on individual and geometric mean steady‐state exposure (top panel: Cmax; middle panel: AUCtau; bottom panel: treatment ratios with 90%CI) to cannabidiol, 7‐OH‐CBD, and 7‐COOH‐CBD. (C) DDI valproate. (i) The effect of concomitant administration of 750 mg of cannabidiol bid on individual and geometric mean steady‐state exposure (top panel: Cmax; middle panel: AUCtau; bottom panel: treatment ratios with 90%CI) to valproate. (ii) The effect of concomitant administration of 750 mg of valproate bid on individual and geometric mean steady‐state exposure (top panel: Cmax; middle panel: AUCtau; bottom panel: treatment ratios with 90%CI) to cannabidiol, 7‐OH‐CBD, and 7‐COOH‐CBD. 7‐OH‐CBD, 7‐hydroxy‐cannabidiol; 7‐COOH‐CBD, 7‐carboxy‐cannabidiol; AUCtau, area under the plasma concentration–time curve over a dosing interval, where tau is the dosing interval; CI, confidence interval; Cmax, maximum concentration; DDI, drug‐drug interaction; N‐CLB, N‐desmethylclobazam; SD, standard deviation.
Figure 4
(A) DDI clobazam. (i) The effect of concomitant administration of 750 mg of cannabidiol bid on individual and geometric mean steady‐state exposure (top panel: Cmax; middle panel: AUCtau; bottom panel: treatment ratios with 90% confidence intervals [CIs]) to clobazam and N‐CLB. (ii) The effect of concomitant administration of 5 mg of clobazam bid, on individual and geometric mean steady‐state exposure (top panel: Cmax; middle panel: AUCtau; bottom panel: treatment ratios with 90%CI) to cannabidiol, 7‐OH‐CBD, and 7‐COOH‐CBD. (B) DDI stiripentol. (i) The effect of concomitant administration of 750 mg of cannabidiol bid on individual and geometric mean steady‐state exposure (top panel: Cmax; middle panel: AUCtau; bottom panel: treatment ratios with 90%CI) to stiripentol. (ii) The effect of concomitant administration of 750 mg of stiripentol bid, on individual and geometric mean steady‐state exposure (top panel: Cmax; middle panel: AUCtau; bottom panel: treatment ratios with 90%CI) to cannabidiol, 7‐OH‐CBD, and 7‐COOH‐CBD. (C) DDI valproate. (i) The effect of concomitant administration of 750 mg of cannabidiol bid on individual and geometric mean steady‐state exposure (top panel: Cmax; middle panel: AUCtau; bottom panel: treatment ratios with 90%CI) to valproate. (ii) The effect of concomitant administration of 750 mg of valproate bid on individual and geometric mean steady‐state exposure (top panel: Cmax; middle panel: AUCtau; bottom panel: treatment ratios with 90%CI) to cannabidiol, 7‐OH‐CBD, and 7‐COOH‐CBD. 7‐OH‐CBD, 7‐hydroxy‐cannabidiol; 7‐COOH‐CBD, 7‐carboxy‐cannabidiol; AUCtau, area under the plasma concentration–time curve over a dosing interval, where tau is the dosing interval; CI, confidence interval; Cmax, maximum concentration; DDI, drug‐drug interaction; N‐CLB, N‐desmethylclobazam; SD, standard deviation.
Figure 4
(A) DDI clobazam. (i) The effect of concomitant administration of 750 mg of cannabidiol bid on individual and geometric mean steady‐state exposure (top panel: Cmax; middle panel: AUCtau; bottom panel: treatment ratios with 90% confidence intervals [CIs]) to clobazam and N‐CLB. (ii) The effect of concomitant administration of 5 mg of clobazam bid, on individual and geometric mean steady‐state exposure (top panel: Cmax; middle panel: AUCtau; bottom panel: treatment ratios with 90%CI) to cannabidiol, 7‐OH‐CBD, and 7‐COOH‐CBD. (B) DDI stiripentol. (i) The effect of concomitant administration of 750 mg of cannabidiol bid on individual and geometric mean steady‐state exposure (top panel: Cmax; middle panel: AUCtau; bottom panel: treatment ratios with 90%CI) to stiripentol. (ii) The effect of concomitant administration of 750 mg of stiripentol bid, on individual and geometric mean steady‐state exposure (top panel: Cmax; middle panel: AUCtau; bottom panel: treatment ratios with 90%CI) to cannabidiol, 7‐OH‐CBD, and 7‐COOH‐CBD. (C) DDI valproate. (i) The effect of concomitant administration of 750 mg of cannabidiol bid on individual and geometric mean steady‐state exposure (top panel: Cmax; middle panel: AUCtau; bottom panel: treatment ratios with 90%CI) to valproate. (ii) The effect of concomitant administration of 750 mg of valproate bid on individual and geometric mean steady‐state exposure (top panel: Cmax; middle panel: AUCtau; bottom panel: treatment ratios with 90%CI) to cannabidiol, 7‐OH‐CBD, and 7‐COOH‐CBD. 7‐OH‐CBD, 7‐hydroxy‐cannabidiol; 7‐COOH‐CBD, 7‐carboxy‐cannabidiol; AUCtau, area under the plasma concentration–time curve over a dosing interval, where tau is the dosing interval; CI, confidence interval; Cmax, maximum concentration; DDI, drug‐drug interaction; N‐CLB, N‐desmethylclobazam; SD, standard deviation.
Similar articles
- A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy.
Ben-Menachem E, Gunning B, Arenas Cabrera CM, VanLandingham K, Crockett J, Critchley D, Wray L, Tayo B, Morrison G, Toledo M. Ben-Menachem E, et al. CNS Drugs. 2020 Jun;34(6):661-672. doi: 10.1007/s40263-020-00726-4. CNS Drugs. 2020. PMID: 32350749 Free PMC article. Clinical Trial. - Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.
Patsalos PN, Szaflarski JP, Gidal B, VanLandingham K, Critchley D, Morrison G. Patsalos PN, et al. Epilepsia. 2020 Sep;61(9):1854-1868. doi: 10.1111/epi.16674. Epub 2020 Sep 12. Epilepsia. 2020. PMID: 32918835 Free PMC article. Review. - A Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate Potential Drug-Drug Interactions Between Cannabidiol and Clobazam.
VanLandingham KE, Crockett J, Taylor L, Morrison G. VanLandingham KE, et al. J Clin Pharmacol. 2020 Oct;60(10):1304-1313. doi: 10.1002/jcph.1634. Epub 2020 Jul 11. J Clin Pharmacol. 2020. PMID: 32652616 Free PMC article. Clinical Trial. - Drug-drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures.
Klein P, Tolbert D, Gidal BE. Klein P, et al. Epilepsy Behav. 2019 Oct;99:106459. doi: 10.1016/j.yebeh.2019.106459. Epub 2019 Sep 10. Epilepsy Behav. 2019. PMID: 31519475 - Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain.
García-Peñas JJ, Gil Nagel-Rein A, Sánchez-Carpintero R, Villanueva-Haba V. García-Peñas JJ, et al. Rev Neurol. 2021 Sep 10;73(S01):S1-S8. doi: 10.33588/rn.73S01.2021250. Rev Neurol. 2021. PMID: 34486101 Review. English, Spanish.
Cited by
- Drug-Cannabinoid Interactions in Selected Therapeutics for Symptoms Associated with Epilepsy, Autism Spectrum Disorder, Cancer, Multiple Sclerosis, and Pain.
Campos MG, China M, Cláudio M, Capinha M, Torres R, Oliveira S, Fortuna A. Campos MG, et al. Pharmaceuticals (Basel). 2024 May 10;17(5):613. doi: 10.3390/ph17050613. Pharmaceuticals (Basel). 2024. PMID: 38794183 Free PMC article. Review. - Evaluation of potential drug-drug interactions with medical cannabis.
Ho JJY, Goh C, Leong CSA, Ng KY, Bakhtiar A. Ho JJY, et al. Clin Transl Sci. 2024 May;17(5):e13812. doi: 10.1111/cts.13812. Clin Transl Sci. 2024. PMID: 38720531 Free PMC article. - CBD and THC in Special Populations: Pharmacokinetics and Drug-Drug Interactions.
Qian L, Beers JL, Jackson KD, Zhou Z. Qian L, et al. Pharmaceutics. 2024 Apr 1;16(4):484. doi: 10.3390/pharmaceutics16040484. Pharmaceutics. 2024. PMID: 38675145 Free PMC article. Review. - Pharmacokinetic Interaction of Kratom and Cannabidiol in Male Rats.
Berthold EC, Kamble SH, Kanumuri SRR, Kuntz MA, Senetra AS, Chiang YH, Mukhopadhyay S, McCurdy CR, Sharma A. Berthold EC, et al. Pharmaceutics. 2024 Feb 24;16(3):318. doi: 10.3390/pharmaceutics16030318. Pharmaceutics. 2024. PMID: 38543213 Free PMC article. - Cannabinoid-Induced Stereoselective Inhibition of R-S-Oxazepam Glucuronidation: Cannabinoid-Oxazepam Drug Interactions.
Bardhi K, Coates S, Chen G, Lazarus P. Bardhi K, et al. Pharmaceutics. 2024 Feb 7;16(2):243. doi: 10.3390/pharmaceutics16020243. Pharmaceutics. 2024. PMID: 38399297 Free PMC article.
References
- Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug‐resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011‐2020. - PubMed
- Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox‐Gastaut syndrome. N Engl J Med. 2018;378(20):1888‐1897. - PubMed
- Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox‐Gastaut syndrome (GWPCARE4): a randomised, double‐blind, placebo‐controlled phase 3 trial. Lancet. 2018;391(10125):1085‐1096. - PubMed
- Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment‐resistant epilepsy: an open‐label interventional trial. Lancet Neurol. 2016;15(3):270‐278. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources